KLRS

Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Wall Street analysts forecast KLRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRS is 21.00 USD with a low forecast of 20.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kalaris Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Kalaris Therapeutics Inc. EPS for the last quarter amounts to -0.64 USD, decreased -97.73 % YoY.

Kalaris Therapeutics Inc (KLRS) has 6 emplpoyees as of December 16 2025.

Today KLRS has the market capitalization of 158.97M USD.